JP2024517788A5 - - Google Patents

Info

Publication number
JP2024517788A5
JP2024517788A5 JP2023567063A JP2023567063A JP2024517788A5 JP 2024517788 A5 JP2024517788 A5 JP 2024517788A5 JP 2023567063 A JP2023567063 A JP 2023567063A JP 2023567063 A JP2023567063 A JP 2023567063A JP 2024517788 A5 JP2024517788 A5 JP 2024517788A5
Authority
JP
Japan
Prior art keywords
day
inhibitor
amino
cdk4
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/053970 external-priority patent/WO2022234409A1/en
Publication of JP2024517788A publication Critical patent/JP2024517788A/ja
Publication of JP2024517788A5 publication Critical patent/JP2024517788A5/ja
Pending legal-status Critical Current

Links

JP2023567063A 2021-05-05 2022-04-28 Ｍｐｎｓｔの処置のための化合物及び組成物 Pending JP2024517788A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184422P 2021-05-05 2021-05-05
US63/184,422 2021-05-05
PCT/IB2022/053970 WO2022234409A1 (en) 2021-05-05 2022-04-28 Compounds and compositions for the treatment of mpnst

Publications (2)

Publication Number Publication Date
JP2024517788A JP2024517788A (ja) 2024-04-23
JP2024517788A5 true JP2024517788A5 (cg-RX-API-DMAC7.html) 2025-05-07

Family

ID=81598046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567063A Pending JP2024517788A (ja) 2021-05-05 2022-04-28 Ｍｐｎｓｔの処置のための化合物及び組成物

Country Status (6)

Country Link
US (1) US20240238284A1 (cg-RX-API-DMAC7.html)
EP (1) EP4333847A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517788A (cg-RX-API-DMAC7.html)
CN (1) CN117177752A (cg-RX-API-DMAC7.html)
TW (1) TW202308631A (cg-RX-API-DMAC7.html)
WO (1) WO2022234409A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP4302834A3 (en) 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
EP3923941B1 (en) * 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and ribociclib

Similar Documents

Publication Publication Date Title
JP2022519375A5 (cg-RX-API-DMAC7.html)
JP2024526145A5 (cg-RX-API-DMAC7.html)
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
JP2022519385A5 (cg-RX-API-DMAC7.html)
JP2022517433A5 (cg-RX-API-DMAC7.html)
JP2019516733A5 (cg-RX-API-DMAC7.html)
JP2021534094A5 (cg-RX-API-DMAC7.html)
JP2016523858A (ja) がんを治療するためのｂｔｋ阻害剤とフルオロウラシルとの併用
JP2015517523A5 (cg-RX-API-DMAC7.html)
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
CN104039148A (zh) 组合als疗法
JP2023524789A5 (cg-RX-API-DMAC7.html)
Punt New drugs in the treatment of colorectal carcinoma
JP2024517788A5 (cg-RX-API-DMAC7.html)
TW201625243A (zh) 用於治療黑素瘤之藥物組合
JP2016505050A5 (cg-RX-API-DMAC7.html)
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
Kaushik et al. Apremilast in orofacial granulomatosis—A report of five cases.
JP2021503448A5 (cg-RX-API-DMAC7.html)
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
JPWO2021206167A5 (cg-RX-API-DMAC7.html)
JP2022504435A5 (cg-RX-API-DMAC7.html)
JP2021512140A5 (cg-RX-API-DMAC7.html)
JP2024518426A5 (cg-RX-API-DMAC7.html)
TW202327579A (zh) Ｔｅａｄ抑制劑的給藥方案